Connect with us

Published

on

Doctors working with Paige technology

Source: Paige

Microsoft announced Thursday it is teaming up with digital pathology provider Paige to build the world’s largest image-based artificial intelligence model for identifying cancer.

The AI model is training on an unprecedented amount of data that includes billions of images, according to a release. It can identify both common cancers and rare cancers that are notoriously difficult to diagnose, and researchers hope it will eventually help doctors who are struggling to contend with staffing shortages and growing caseloads.

Paige develops digital and AI-powered solutions for pathologists, which are doctors who carry out lab tests on bodily fluids and tissues to make a diagnosis. It’s a specialty that often operates behind the scenes, and it’s crucial for determining a patient’s path forward.

“You don’t have cancer until the pathologist says so. That’s the critical step in the whole medical edifice,” Thomas Fuchs, co-founder and chief scientist at Paige, told CNBC in an interview.

But despite pathologists’ essential role in medicine, Fuchs said their workflow has not changed much in the last 150 years. To diagnose cancer, for instance, pathologists usually examine a piece of tissue on a glass slide under a microscope. The method is tried and true, but if pathologists miss something, it can have dire consequences for patients.

As a result, Paige has been working to digitize the pathologists’ workflow to improve accuracy and efficiency within the specialty.

Doctors working with Paige technology

Source: Paige

The company has received approval from the Food and Drug Administration for its viewing tool FullFocus, which allows pathologists to examine scanned digital slides on a screen instead of relying on a microscope. Paige also built an AI model that can help pathologists identify breast cancer, colon cancer and prostate cancer when it appears on the screen.

Digital pathology is costly

Paige is the only company that has received FDA approval for pathologists to use its AI as a secondary tool for identifying prostate cancer, and CEO Andy Moye said this is likely in part because of barriers related to storage costs and data collection.

Digitizing a single slide can require over a gigabyte of storage, so the infrastructure and costs associated with large-scale data collection balloon quickly. Fuchs said the storage costs can be inhibiting for smaller health systems, which is why wealthy academic centers have historically been the only organizations that can afford to invest in digital pathology.

Paige spun out of the Memorial Sloan Kettering Cancer Center in New York in 2017 and has a “fantastic wealth of data,” according to Moye, which is why the company was able to build its own AI-powered solutions in the first place. To put the scale in perspective, Paige has 10 times more data than Netflix, including all the shows and movies that exist on the platform.

But in order to expand its operations and build an AI tool that can identify more cancer types, Paige turned to Microsoft for help. Over the past year and a half, Paige has been using Microsoft’s cloud storage and supercomputing infrastructure to build an advanced new AI model.

Paige’s original AI model used more than 1 billion images from 500,000 pathology slides, but Fuchs said the model the company has built with Microsoft is “orders of magnitude larger than anything out there.” The model is training on 4 million slides to identify both common and rare cancers, which can be difficult to diagnose. Paige said it is the largest computer vision model that has ever been announced publicly.

“Until ChatGPT got released, no one really understood how this is going to impact their lives. I would argue this is very similar for cancer patients going forward,” Moye said. “This is sort of a groundbreaking, land-on-the-moon kind of moment for cancer care.”

Moye added that the company is thinking of ways to incorporate predictive modeling to give pathologists and patients easy access to information about their biomarkers and genomic mutations down the line.

Desney Tan, vice president and managing director of Microsoft Health Futures, said Microsoft’s infrastructure is a key component of the partnership, but that the company is also working to develop the new algorithms, detection and diagnostics that Paige is hoping to deliver in the next couple of years.

He added that though the technology is powerful, it’s meant to enrich pathologists, not replace them.

“We think of these AI implements, these technologies, as tools, really just as the stethoscope is a tool, just as the X-ray machine is a tool,” Tan told CNBC in an interview. “AI is a tool that is to be wielded by a human.”

On Thursday, Paige and Microsoft will publish a paper on the model through Cornell University’s preprint server arXiv. The paper quantifies the impact of the new model compared with existing models, and Fuchs said it outperforms anything that has been built in academia up to this point.

But the preprint is just the first step of a much longer journey. Paige wanted to make the research available to the broader community while it is under peer review, and the company intends to submit to the scientific journal Nature. The process can take months, if not longer. Paige also has years of work ahead before it will be able to roll the model out as a product — including thorough testing and collaboration with regulators to ensure it is safe and accurate.

Ultimately, Fuchs said the AI model will solve the storage problem for health systems, while also helping pathologists work through cases and arrive at a diagnosis more quickly. For some patients, it could mean the difference between waiting two days and two weeks to find out what’s wrong.

“The more you go away from academic medical centers, especially in community clinics where pathologists are completely overwhelmed across all cancer types with so many cases, there, the impact is quite drastic,” Fuchs said. “That really helps to democratize access to health care in these places.”

Continue Reading

Technology

Amazon adds pet prescriptions to its online pharmacy

Published

on

By

Amazon adds pet prescriptions to its online pharmacy

Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. 

Smith Collection | Gado | Getty Images

Amazon is expanding its online pharmacy to fill prescription pet medications, the company announced Thursday.

The company said it has added “hundreds of commonly prescribed pet medications” to its U.S. site, ranging from flea and tick solutions to treatments for chronic conditions.

Prescriptions are purchased via Amazon’s storefront and must be approved by a veterinarian. Online pet pharmacy Vetsource will oversee the dispensing and delivery of medications, said Amazon, adding that items are typically delivered within two to six days.

Amazon launched its digital drugstore in 2020 with the added perk of discounts and free delivery for Prime members. The company has been working to speed up prescription shipments over the past year, bringing same-day delivery to a handful of U.S. cities. Last October, Amazon set a goal to make speedy medicine delivery available in nearly half of the U.S. in 2025.

The new pet medication offerings puts Amazon into more direct competition with online pet pharmacy Chewy, as well as Walmart, which offers pet prescription delivery.

Amazon Pharmacy is part of the company’s growing stable of healthcare offerings, which also includes One Medical, the primary care provider it acquired for roughly $3.9 billion in July 2022. Amazon’s online pharmacy was born out of the company’s 2018 acquisition of online pharmacy PillPack.

WATCH: Amazon’s new Vulcan robot can ‘feel’ what it touches

Here's a first look at Vulcan, Amazon's new stowing robot that can feel what it touches

Continue Reading

Technology

Coinbase acquires crypto derivatives exchange Deribit for $2.9 billion

Published

on

By

Coinbase acquires crypto derivatives exchange Deribit for .9 billion

The Coinbase logo is displayed on a smartphone with stock market percentages on the background.

Omar Marques | SOPA Images | Lightrocket | Getty Images

Coinbase agreed to acquire Dubai-based Deribit, a major crypto derivatives exchange, for $2.9 billion, the largest deal in the crypto industry to date.

The company said Thursday that the cost comprises $700 million in cash and 11 million shares of Coinbase class A common stock. The transaction is expected to close by the end of the year.

Shares of Coinbase rose nearly 6%.

The acquisition positions Coinbase as an international leader in crypto derivatives by open interest and options volume, Greg Tusar, vice president of institutional product, said in a blog post – which could allow it take on big players like Binance. Coinbase operates the largest marketplace for buying and selling cryptocurrencies within the U.S., but has a smaller share of the global crypto market, where activity largely takes place on Binance.

Deribit facilitated more than $1 trillion in trading volume last year and has about $30 billion of current open interest on the platform.

“We’re excited to join forces with Coinbase to power a new era in global crypto derivatives,” Deribit CEO Luuk Strijers said in a statement. “As the leading crypto options platform, we’ve built a strong, profitable business, and this acquisition will accelerate the foundation we laid while providing traders with even more opportunities across spot, futures, perpetuals, and options – all under one trusted brand. Together with Coinbase, we’re set to shape the future of the global crypto derivatives market.”

Tusar also noted that Deribit has a “consistent track record” of generating positive adjusted EBITDA the company believes will grow as a combined entity.  

“One of the things we liked most about this deal is that it’s not just a game changer for our international expansion plans — it immediately diversifies our revenue and enhances profitability,” Tusar told CNBC.

The deal comes at a time when the crypto industry is riding regulatory tailwinds from the first ever pro-crypto White House. Support of the industry has fueled crypto M&A activity in recent weeks. In March, crypto exchange Kraken agreed to acquire NinjaTrader for $1.5 billion, and last month Ripple agreed to buy prime broker Hidden Road.

Don’t miss these cryptocurrency insights from CNBC Pro:

Continue Reading

Technology

Whoop launches two new wearables with 14-day battery life

Published

on

By

Whoop launches two new wearables with 14-day battery life

Whoop member wears the new device.

Courtesy of Whoop

Whoop on Thursday announced two new wearable devices, Whoop 5.0 and Whoop MG, which feature sleeker hardware, a longer battery life and additional in-app health insights. 

Both of the company’s new devices are designed for 24/7 wear.

The Whoop 5.0 and Whoop MG support 14 days of battery life, which is around triple the four-to-five-day range offered by Whoop 4.0. The new hardware is also 7% smaller than the previous device, with a processor that’s 60% faster, the company said. 

“We’ve taken everything we’ve learned over the past decade and built a platform to help our members perform and live at their peak for longer,” Whoop founder and CEO Will Ahmed said in a release. 

The launch marks Whoop’s first major hardware update since 2021, when the company released Whoop 4.0. Whoop said its new devices will help users understand how their daily decisions impact their performance and health outcomes over time, according to a release.

Cost and tiers

There are three annual membership tiers: Whoop One, which costs $199 and includes the Whoop 5.0; Whoop Peak, which costs $239 and includes the Whoop 5.0; and Whoop Life, which costs $359 and includes the Whoop MG. Accessories like additional bands will come at an extra cost.

Whoop 5.0 and Whoop MG memberships and accessories are available for purchase online starting on Thursday.

Whoop’s new membership options.

Whoop

Whoop One members will be able to use their Whoop 5.0 to measure sleep, strain and recovery, as well as the cardiovascular and muscular impact of various workouts. Users can also track their menstrual cycles and pregnancies. 

Whoop Peak builds on those core metrics. Members have access to a Health Monitor feature, which provides a quick look at vitals like respiratory rate, heart rate, blood oxygen, and skin temperature. Whoop Peak also supports a real-time stress monitor, where users can see their stress level and complete guided breathing sessions if they’d like to increase relaxation or alertness. 

The company also unveiled a feature called Healthspan, which uses nine metrics to calculate adult users’ Whoop Age and Pace of Aging. A user’s Whoop Age compares their physiological age to their actual age, and Pace of Aging assesses how fast or slow someone is aging based on their behavior. 

The Healthspan feature is updated every week, and users will get tips about how they can improve their Whoop Age and Pace of Aging in their app. Whoop developed this feature in partnership with the Buck Institute for Research on Aging, the company said. 

The most comprehensive membership is Whoop Life, which will give users access to additional medical-grade health features with Whoop MG.  

Whoop Life members can record an electrocardiogram, or an ECG, to detect irregular heart rhythms like AFib, high heart rate or low heart rate. Once the reading is complete, they can share a PDF of the recording with their doctor. 

The ECG feature has been cleared by the U.S. Food and Drug Administration. It’s not intended for users under 22 years old, or for users with a cardiac pacemaker or other implanted devices. It will be available in the U.S., the UAE and Qatar at launch, with additional countries coming soon. 

Whoop Life members can also get daily insights about their blood pressure, including estimated systolic and diastolic ranges. Users will have to log a traditional cuff-reading to act as a baseline to unlock this feature, and it’s not intended for treatment, diagnosis or medical use.  

Whoop said Blood Pressure Insights has been in development for several years, and the feature is currently in beta.  

Quick takeaways

Ashley Capoot wearing Whoop MG

Ashley Capoot

I got a sneak peek at the Whoop MG, and I’ve been wearing it for the past few days. I can’t speak to what it’s like to wear the device over an extended period, but my initial experience has been largely positive. 

From a hardware standpoint, the Whoop MG looks and feels sleeker than the Whoop 4.0, which I tested out in April. The actual sensor is roughly an inch wide, and the band is slightly thinner than that. I’ve found that both the Whoop MG and the Whoop 4.0 are a little hard to take off — you really have to tug on the latch. 

The Whoop MG’s setup is very straightforward, and I was up and running on the app in a matter of minutes. With all the new features, there’s a lot of additional data to make sense of, so the app seemed pretty busy to me at first. I felt like I had a better handle on it after a few hours, though, and I haven’t felt pressure to constantly monitor it.  

Of the new features, I thought Healthspan was particularly interesting. As a relatively healthy 24-year-old, I noticed I still felt relieved to be “younger” than my age. I’d be curious to see how that feature would change based on my behaviors from week to week. 

I also liked the Whoop MG’s detailed sleep tracking and the real-time stress monitor, as stress is something I’ve personally been trying to be more mindful of. I’ve learned that my stress levels really skyrocket while I’m taking public transport, for instance, and adjust accordingly.

After about a dozen tries, I wasn’t able to log a successful ECG reading. I kept getting errors, even after switching wrists and the positioning of my arms. That’s been disappointing, as I’m interested to see my results. The Blood Pressure Insights are neat, and assuming other users can successfully record ECG readings, it’s easy to see the potential benefit. That said, I don’t think I need those features in my daily life yet, so the Whoop Life membership probably wouldn’t be the right pick for me. 

I’m not totally sold on the Whoop MG’s aesthetics. I have small hands and wrists, so I always feel like smart devices tend to look clunky on me. 

I definitely felt like the Whoop 4.0 was too big for me, but the Whoop MG doesn’t bother me quite as much. That’s just my personal taste, and there are lots of Whoop accessories you can buy to spiff up the device for different occasions. 

After just a few days, there’s a lot I can still learn from the Whoop MG, but I feel like I’d personally reach for the Whoop 5.0. The range of membership options helps ensure that users don’t have to break the bank, so I’d feel comfortable recommending Whoop 5.0 and Whoop MG to my friends and family. And for existing Whoop customers who are thinking about an upgrade, the extended battery life alone is worth considering. 

WATCH: CEO of fitness tracker company Whoop on $3.6 billion valuation, outlook

CEO of fitness tracker company Whoop on $3.6 billion valuation, outlook

Continue Reading

Trending